Johnson & Johnson (JNJ) Other Gross PP&E Adjustments (2009 - 2026)

Johnson & Johnson's (JNJ) quarterly Other Gross PP&E Adjustments came in at $49.6 billion in Q1 2026, up 8.09% year-on-year from $45.9 billion in Q1 2025, and down 8.77% quarter-over-quarter from $54.4 billion in Q4 2025.

Johnson & Johnson (JNJ) Other Gross PP&E Adjustments (2009 - 2026) Analysis & Trends

Johnson & Johnson has disclosed Other Gross PP&E Adjustments across 18 years of filings, most recently posting $49.6 billion for Q1 2026.

  • Other Gross PP&E Adjustments for Q1 2026 came in at $49.6 billion, up 8.09% year-over-year; the trailing twelve-month figure through Mar 2026 was $49.6 billion (up 8.09% YoY), and the FY2025 annual result was $54.4 billion, up 11.47% from the prior year.
  • Other Gross PP&E Adjustments came in at $49.6 billion for Q1 2026 at Johnson & Johnson, down from $54.4 billion in the prior quarter.
  • In the past five years, Other Gross PP&E Adjustments ranged from a high of $54.4 billion in Q4 2025 to a low of $41.1 billion in Q4 2023.
  • The 5-year median for Other Gross PP&E Adjustments is $45.7 billion (2023), against an average of $46.0 billion.
  • Across the five-year window, Other Gross PP&E Adjustments soared 5305.78% in 2022 and slipped 8.69% in 2023, its largest moves.
  • Johnson & Johnson's Other Gross PP&E Adjustments stood at $42.4 billion in 2022, then advanced by 12.73% to $47.8 billion in 2023, then gained by 2.08% to $48.8 billion in 2024, then rose by 11.47% to $54.4 billion in 2025, then slipped by 8.77% to $49.6 billion in 2026.
  • The last three Other Gross PP&E Adjustments figures came in at $49.6 billion (Q1 2026), $54.4 billion (Q4 2025), and $48.9 billion (Q3 2025), per Business Quant data.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Other Gross PP&E Adjustments (Qtr)
1 Gsk 96,436,181.12 Bn 96,436,176.16 Bn 7.76 Bn -941.03 Mn
2 Eli Lilly 1,017.30 Bn 1,012.01 Bn 16.22 Bn -
3 Johnson & Johnson 579.61 Bn 557.55 Bn 15.96 Bn 49.60 Bn
4 AbbVie 402.30 Bn 392.96 Bn 10.78 Bn -
5 Merck 294.24 Bn 288.59 Bn 12.09 Bn -
6 Amgen 191.82 Bn 179.78 Bn 5.87 Bn -2.70 Bn
7 Gilead Sciences 155.93 Bn 148.21 Bn 5.52 Bn 8.42 Bn
8 Pfizer 149.05 Bn 136.28 Bn -1.21 Bn -
9 Bristol Myers Squibb 116.33 Bn 105.88 Bn 8.07 Bn -1.53 Bn
10 Novartis Ag 112.59 Bn 111.90 Bn - -

Historic Data

Download Data
DateValue
Mar 29, 2026 49.60 Bn
Mar 29, 2026 49.60 Bn
Dec 28, 2025 54.36 Bn
Dec 28, 2025 54.36 Bn
Sep 28, 2025 48.88 Bn
Sep 28, 2025 48.88 Bn
Jun 29, 2025 47.97 Bn
Jun 29, 2025 47.97 Bn
Mar 30, 2025 45.88 Bn
Mar 30, 2025 45.88 Bn
Dec 29, 2024 48.77 Bn
Dec 29, 2024 48.77 Bn
Sep 29, 2024 44.77 Bn
Sep 29, 2024 44.77 Bn
Jun 30, 2024 43.54 Bn
Jun 30, 2024 43.54 Bn
Mar 31, 2024 43.29 Bn
Mar 31, 2024 43.29 Bn
Dec 31, 2023 47.78 Bn
Dec 31, 2023 47.78 Bn